Trial Profile
An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2005
Price :
$35
*
At a glance
- Drugs Ortataxel (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 16 Sep 2005 New trial record.